Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

891505

	registered interest
	date	25/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the timetable is for the introduction of an outcomes-based payment approach for (a) manufacturers and (b) providers of (i) medical devices, (ii) medical diagnostics, and (iii) health apps; and if he will make a statement.
	tabling member constituency	Shipley
	tabling member printed	Philip Davies
	uin	138012
	answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>A fee-for-service payment system, where each individual element of care is charged for separately, does not operate in the National Health Service in England. Generally, acute services are paid for on the basis of complete spells in hospital. With the exception of some high cost drugs and devices, this includes the costs of all devices, diagnostics and any other costs associated with the care whilst in hospital.</p><p> </p><p>NHS England is exploring new ways of managing payment for health apps, including a consideration of outcome based payment models.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 03/05/2018 13:00:51 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1565 label Biography information for Sir Philip Davies

891503

	registered interest
	date	25/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Asians
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the prevalence of (a) type 1 and (b) type 2 diabetes is amongst people of South Asian origin, in (i) each parliamentary constituency, (ii) each clinical commissioning group, and (iii) in England, in the most recent year for which data is available.
	tabling member constituency	Shipley
	tabling member printed	Philip Davies
	uin	138010
	answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>Data on the prevalence of type 1 and type 2 diabetes among people of South Asian origin, in each parliamentary constituency, each clinical commissioning group, and in England, are not published in the format requested.</p><p> </p><p>The National Diabetes Audit (NDA) reports that approximately 8% of those with type 1 diabetes are from a minority ethnic origin and approximately 19% of those with type 2 diabetes are from a minority ethnic origin.</p><p> </p><p>The NDA records the ethnicity of diabetes patients (and other patient characteristics). Information on ethnicity is split by White/ Minority Ethnic Origin and Unknown. Minority ethnic origin includes South Asian, Chinese and other Asian, black, mixed and other ethnicities. The NDA routinely monitors the effects of ethnicity on patient outcomes, percentage of patients receiving National Institute for Health and Care Excellence’s (NICE’s) recommended eight care processes; achievement of NICE treatment targets and diabetic complications. Further information is available at the following link:</p><p> </p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-report-1-findings-and-recommendations-2016-17" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-report-1-findings-and-recommendations-2016-17</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 138011 question first answered 03/05/2018 13:26:07 answering member 4067 label Biography information for Steve Brine
	tabling member	1565 label Biography information for Sir Philip Davies

891504

	registered interest
	date	25/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Asians
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to monitor the effect of diabetes in people of South Asian origin in England.
	tabling member constituency	Shipley
	tabling member printed	Philip Davies
	uin	138011
	answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>Data on the prevalence of type 1 and type 2 diabetes among people of South Asian origin, in each parliamentary constituency, each clinical commissioning group, and in England, are not published in the format requested.</p><p> </p><p>The National Diabetes Audit (NDA) reports that approximately 8% of those with type 1 diabetes are from a minority ethnic origin and approximately 19% of those with type 2 diabetes are from a minority ethnic origin.</p><p> </p><p>The NDA records the ethnicity of diabetes patients (and other patient characteristics). Information on ethnicity is split by White/ Minority Ethnic Origin and Unknown. Minority ethnic origin includes South Asian, Chinese and other Asian, black, mixed and other ethnicities. The NDA routinely monitors the effects of ethnicity on patient outcomes, percentage of patients receiving National Institute for Health and Care Excellence’s (NICE’s) recommended eight care processes; achievement of NICE treatment targets and diabetic complications. Further information is available at the following link:</p><p> </p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-report-1-findings-and-recommendations-2016-17" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-report-1-findings-and-recommendations-2016-17</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 138010 question first answered 03/05/2018 13:26:07 answering member 4067 label Biography information for Steve Brine
	tabling member	1565 label Biography information for Sir Philip Davies

891482

	registered interest
	date	25/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pregnancy: Sodium Valproate
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what representations his Department and its agencies have received on the resources necessary to improve patient safety and engage with health professionals to raise awareness of the potential health risks for women of child-bearing age taking Sodium Valproate; and if he will make a statement.
	tabling member constituency	Chesham and Amersham
	tabling member printed	Dame Cheryl Gillan
	uin	137887
	answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is working in partnership with the Department, professional bodies and the healthcare system to deliver a package of measures to raise awareness of the significant risks associated with sodium valproate in pregnancy and to support healthcare professionals in reducing the harms from valproate in women of child-bearing age and improving patient safety in line with the strengthened regulatory position. Educational materials for healthcare professionals and patients are being sent to general practitioners (GP) and specialist prescribers. The National Institute for Health and Care Excellence has updated its guidelines which mention valproate to reflect the new regulatory measures. GP electronic system providers have provided a search and audit function to facilitate the identification of women of childbearing age on valproate and are updating the alerts for valproate.</p><p> </p><p>All parties involved are fully committed to this important work using the resources available from each relevant organisation. In addition, since 2016 the MHRA has been working with a network of over 40 stakeholder organisations (termed the Valproate Stakeholders’ Network) to foster cross-sector support for the new measures and leverage their collective communications reach.</p><p> </p><p>The effectiveness of the new measures in reducing prescribing of valproate in women of childbearing potential will be closely monitored. Relevant data will be published and there will be ongoing follow-up to ensure that the harms to the child from valproate in pregnancy are minimised.</p><p> </p><p>I would particularly like to thank the families involved in the Valproate Stakeholder Network who have shared their experiences and expertise. Their dedication, support and altruism will help to keep future generations of children safe.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 03/05/2018 12:59:46 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	18 label Biography information for Dame Cheryl Gillan

891382

	registered interest
	date	25/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gambling
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of people who have a gambling addiction.
	tabling member constituency	West Bromwich East
	tabling member printed	Tom Watson
	uin	137978
	answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>Estimates of the numbers of people who are problem gamblers are not readily available, but the Health Survey for England does provide percentage prevalence rates. In 2016, 0.7% of people in England were identified as problem gamblers.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/05/2018 13:28:27 answering member 4067 label Biography information for Steve Brine
	tabling member	1463 label Biography information for Lord Watson of Wyre Forest

891407

	registered interest
	date	25/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hospitals: Parking
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of NHS Foundation Trust hospital car parks in England use pay on exit facilities.
	tabling member constituency	Harlow
	tabling member printed	Robert Halfon
	uin	138025
	answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>The data is not collected in the format requested.</p><p> </p><p>The Patient Led Assessment of the Care Environment (PLACE) system assesses the quality of the patient environment. It is a voluntary self-assessment which takes place annually, and applies to hospitals, hospices, and day treatment centres providing National Health Service-funded care. PLACE includes questions on car parking relating to the charging, concessions, and payment methods.</p><p> </p><p>The 2017 PLACE data shows:</p><p> </p><p>Total number of sites with payment on exit facilities (respondents) = 244</p><p>Number responded yes: 144 = 59%</p><p>Number responded no: 100 = 41%</p><p> </p><p> </p><p>Total number of trusts with payment on exit facilities (respondents) = 118</p><p>Number responded yes: 94 = 80%</p><p>Number responded no: 24 = 20%</p><p> </p><p>The total number of organisations (including NHS Trusts) that responded was 279, providing assessment of 1,230 sites. All PLACE data is published at:</p><p> </p><p><a href="http://hefs.hscic.gov.uk/PLACE.asp" target="_blank">http://hefs.hscic.gov.uk/PLACE.asp</a></p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay question first answered 03/05/2018 14:56:48 answering member 4095 label Biography information for Steve Barclay
	tabling member	3985 label Biography information for Robert Halfon

891363

	registered interest
	date	25/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Motor Neurone Disease: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress has been made on the development of treatments for motor neurone disease.
	tabling member constituency	Belfast North
	tabling member printed	Nigel Dodds
	uin	137965
	answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>Treatment for motor neurone disease (MND) can include a range of approaches such as counselling and emotional support, respiratory care, speech and language therapy, physiotherapy, respiratory secretion management, neurorehabilitation, physiotherapy and palliative care. Whilst drugs can be used for symptom management, riluzole is the only pharmacological drug licensed in the United Kingdom to slow the progression of MND.</p><p><br> Through the National Institute for Health Research (NIHR), we are investing over £1 billion a year in health research. In 2016-17, the NIHR invested £4.58 million to fund and support a range of research studies and infrastructure with a focus on MND and closely-related conditions. Current research falls in to three broad categories:</p><p>- Drugs that will slow down or cure MND;</p><p>- Improving care, symptom management and quality of life for people with MND; and</p><p>- Work to better categorise patients with MND so that treatments can be personalised.</p><p>Examples of drug research include the first gene therapy studies for a type of MND that runs in families, and a multicentre academic European Union and MND Association funded study of interleukin-2 to assess whether it can slow progression by reducing the immune system response.</p><p><br> <br> The NIHR welcomes funding applications for research into any aspect of human health, including MND. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p>The Medicines and Healthcare products Regulatory Authority has also advised that it is aware of five active clinical trials into treatments for MND.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/05/2018 13:19:20 answering member 4067 label Biography information for Steve Brine
	tabling member	1388 label Biography information for Lord Dodds of Duncairn

891458

	registered interest
	date	25/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Primary Health Care: Data Protection
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the quantum of associated costs of implementing the General Data Protection Regulation for (a) pharmacists, (b) dentists, (c) optometrists, (d) general practitioners and (e) other NHS primary care contractors.
	tabling member constituency	Burnley
	tabling member printed	Julie Cooper
	uin	138069
	answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>It is the responsibility of each organisation to ensure their compliance with the General Data Protection Regulation which comes into effect on 25 May 2018. For the past year we have been working alongside system partners across health and social care in developing a comprehensive suite of guidance products to help organisations recognise their obligations and help put effective governance and risk management arrangements in place from 25 May. These guidance materials are available to all health and care organisations on the NHS Digital website and will include guidance to general practice, optometry, pharmaceutical and dental organisations. In addition, there is considerable information and guidance available from the Information Commissioner’s Office.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 138068 question first answered 03/05/2018 13:03:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4405 label Biography information for Julie Cooper

891456

	registered interest
	date	25/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Primary Health Care: Data Protection
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect of the General Data Protection Regulation on (a) pharmacists, (b) dentists, (c) optometrists, (d) general practitioners and (e) other NHS primary care contractors.
	tabling member constituency	Burnley
	tabling member printed	Julie Cooper
	uin	138068
	answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>It is the responsibility of each organisation to ensure their compliance with the General Data Protection Regulation which comes into effect on 25 May 2018. For the past year we have been working alongside system partners across health and social care in developing a comprehensive suite of guidance products to help organisations recognise their obligations and help put effective governance and risk management arrangements in place from 25 May. These guidance materials are available to all health and care organisations on the NHS Digital website and will include guidance to general practice, optometry, pharmaceutical and dental organisations. In addition, there is considerable information and guidance available from the Information Commissioner’s Office.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 138069 question first answered 03/05/2018 13:03:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4405 label Biography information for Julie Cooper

891471

	registered interest
	date	25/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Muscular Dystrophy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the suitability of the Single Technology Appraisal process for new treatments for patients with Duchenne Muscular Dystrophy.
	tabling member constituency	Chesham and Amersham
	tabling member printed	Dame Cheryl Gillan
	uin	137885
	answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent an effective use of NHS resources.</p><p> </p><p>NICE assesses most significant new drugs through its technology appraisal programme and has been able to recommend a number of drugs licenced for the treatment of rare diseases for routine use on the NHS. NICE also operates a separate highly specialised technology (HST) evaluation programme for the assessment of very high cost drugs for the treatment of very small numbers of patients. Decisions on the most appropriate programme for individual drugs and other treatments are made through an established topic selection process that includes a public consultation and thorough consideration against a set of published criteria.</p><p> </p><p>NICE published HST guidance recommending ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in July 2016 and is currently developing guidance, through its technology appraisal and HST programmes, on other drugs for the treatment of Duchenne muscular dystrophy.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/05/2018 15:58:20 answering member 4067 label Biography information for Steve Brine
	tabling member	18 label Biography information for Dame Cheryl Gillan